Is Immunocore Holdings plc (IMCR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 26.2% / 30% | 51.7% / 30% | 6.1% / 30% | 4.12% / 5% | ✗ NOT HALAL |
| DJIM | 26.2% / 33% | 51.7% / 33% | 6.1% / 33% | 4.12% / 5% | ✗ NOT HALAL |
| MSCI | 40.9% / 33% | 81.0% / 33% | 9.5% / 33% | 4.12% / 5% | ✗ NOT HALAL |
| S&P | 26.2% / 33% | 51.7% / 33% | 6.1% / 33% | 4.12% / 5% | ✗ NOT HALAL |
| FTSE | 40.9% / 33% | 81.0% / 33% | 9.5% / 50% | 4.12% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 96.5% | |
| Operating Margin | 0.0% | |
| Net Margin | -8.9% | |
| Return on Equity (ROE) | -9.6% | |
| Return on Assets (ROA) | -1.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$15M |
| Total Debt | $437M |
| Debt-to-Equity | 114.6 |
| Current Ratio | 4.0 |
| Total Assets | $1.1B |
Price & Trading
| Last Close | $30.51 |
| 50-Day MA | $32.33 |
| 200-Day MA | $33.86 |
| Avg Volume | 416K |
| Beta | 0.8 |
|
52-Week Range
$23.15
| |
About Immunocore Holdings plc (IMCR)
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Immunocore Holdings plc (IMCR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Immunocore Holdings plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Immunocore Holdings plc's debt ratio?
Immunocore Holdings plc's debt ratio is 26.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 40.9%.
What are Immunocore Holdings plc's key financial metrics?
Immunocore Holdings plc has a market capitalization of $1.5B, and revenue of $400M. The company maintains a gross margin of 96.5% and a net margin of -8.9%. Return on equity stands at -9.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.